Rhythm Pharmaceuticals up 28% on an AstraZeneca bid report. Its 8-K never mentions a deal
Kyndryl rose 30%, Rhythm 28% and Duolingo 26% on Nov. 4. Two moved on earnings that filings confirm; Rhythm moved on a reported $10 billion AstraZeneca offer that the company has not filed anything about.

Basis: Nov. 5, 2026 KST; prices are regular-session closes on Nov. 4 (U.S.)

Seoul — U.S. stocks rose on Nov. 4, with the S&P 500 up 1.58% to 7,688.62, the Nasdaq up 1.44% to 25,736.51 and the Russell 2000 small-cap index up 1.58% to 2,856.95. The biggest movers were Kyndryl Holdings, Inc. (KD) at +30.14%, Rhythm Pharmaceuticals, Inc. (RYTM) at +28.04% and Duolingo, Inc. (DUOL) at +25.99%. Kyndryl and Duolingo have earnings releases on file with the SEC, while Rhythm rose on a bid report and its own filings say nothing about a deal.
At a glance
| Stock | Move (close) | Close | Dollar volume | Why it rose | Nature | Basis | Heat | What to check next |
|---|---|---|---|---|---|---|---|---|
| Kyndryl (KD) | +30.14% | $16.84 | ~$252M | Q2 beat reported; full-year outlook kept | Substance, one-off | Filing confirms the release only; figures per press reports | 0/4 normal | Next quarter's results; shrinking revenue |
| Rhythm (RYTM) | +28.04% | $110.68 | ~$598M | Reported $10B AstraZeneca offer | Expectation | Press reports only; no filing | 1/4 caution | An official statement or 8-K |
| Duolingo (DUOL) | +25.99% | $161.27 | ~$1.53B | Earnings release, analyst target raises | Substance, ongoing | Filing confirms the release only; figures per press reports | 1/4 caution | Next-quarter revenue growth; Nov. 4 Form 144 |
The jobs report on Nov. 6 and CPI on Nov. 10 are next on the calendar and are a shared risk for all three.
Rhythm Pharmaceuticals rose 28% on a reported AstraZeneca bid (no filing backs it)
Rhythm Pharmaceuticals jumped on a report that AstraZeneca offered about $10 billion for the company. TradingView headlined it as the stock's best day in nearly 16 months on the AstraZeneca $10B bid report, and Yahoo Finance UK carried the same story. The stock closed at $110.68 after falling 7.49% to $86.44 the day before.
The company's filings do not mention a deal. The only filing in the past seven days is an 8-K dated Nov. 3 under Items 2.02 and 9.01, which attaches the third-quarter earnings release and a presentation. Yahoo Finance Singapore also ran a story on a $750 million financing, and Benzinga reported positive UK NICE guidance on the company's drug Imcivree for adults with Bardet-Biedl syndrome. Neither supports the bid report directly.
If accurate, the figure is large: $10 billion is about 30% above the roughly $7.7 billion market value at the close, though that may not reflect any newly issued shares. Volume was 5.3 times the 20-day average and RSI 73.6. The price sits 22.0% above its 20-day average, giving 1 of 4 overheating signals (caution). It is 5.9% below its 52-week high and 14.1% above its 200-day average. Fundamentals pass 2 of 6 checks (passed: debt level, revenue growth of 46.9%; failed: profitability, free cash flow, ROE of 10%, P/E of 25 or less). No filing in the past week is neutral or otherwise.
What decides whether this holds is whether the company or AstraZeneca confirms talks officially, for example in an 8-K. If it stays a press report alone, the gain may unwind. No Form 4 or 144 insider filings appear in the past seven days.
Kyndryl rose 30% after a second-quarter beat
Kyndryl rose 30.14% after reporting fiscal second-quarter 2027 results. Its 8-K (Items 2.02 and 9.01) only attaches the earnings release, and the text carries no revenue or profit figures. GuruFocus reported a beat of estimates with the fiscal 2027 outlook reaffirmed, and a Yahoo call summary said management held its outlook as workforce savings ramp up. The outlook was kept, not raised.
The stock had slid from $15.20 on Oct. 22 to $12.94 on Nov. 3 before jumping to $16.84. Latest data show revenue down 3.3% and a P/E of 45.5. Fundamentals pass 2 of 6 checks (passed: profitability, free cash flow; failed: debt level, ROE of 10%, revenue growth, P/E of 25 or less). Volume was 3.8 times normal, so overheating signals are 0 of 4 (normal), though the price is 24.1% above its 20-day average with RSI at 72.3. It remains 38.8% below its 52-week high. About $252 million traded, roughly 7% of its $3.7 billion market value.
To judge whether it lasts, watch whether cost savings show up as profit next quarter and whether shrinking revenue turns. This is a reaction to one earnings report. No Form 4 or 144 appears in the past seven days.
Duolingo rose 26% after earnings, with a fifth of its market value traded in one day
Duolingo reported earnings after the close on Nov. 3 and rose 25.99% the next day to $161.27. Its 8-K (Items 2.02 and 9.01) attaches the earnings release and a shareholder letter but gives no figures in the text. Headlines from MarketBeat and GuruFocus show Citigroup, JPMorgan, Barclays and Scotiabank raising price targets.
About $1.53 billion traded, roughly 20% of its $7.5 billion market value, and volume was 10 times the 20-day average. It shows 1 of 4 overheating signals (caution), with RSI at 57.6 and the price 14.0% above its 20-day average. It is 38.0% below its 52-week high and 30.3% above its 200-day average. Fundamentals pass all 6 checks, with a P/E of 19.2 and revenue growth of 18.3%. Separately, Kaplan Fox published a notice about a securities class action against the company with a Dec. 7 deadline; no link to today's move is established.
To see whether it holds, watch whether revenue growth stays near 18.3% next quarter, and what the Form 144 (a notice of planned insider selling) filed on Nov. 4 covers; its size is not shown here. A 13G/A ownership update was also filed on Oct. 30.
How earlier picks fared
Close-to-close changes since our earlier articles, by verdict (periods differ by article date):
| Verdict | Stock (article date) | Since |
|---|---|---|
| Earnings | IDEXX Laboratories (11/3) | +4.0% |
| Earnings | Newell Brands (11/3) | -1.7% |
| Earnings | Glaukos Corporation (10/30) | +1.7% |
| Earnings | Bausch Health Companies Inc. (10/30) | -6.4% |
| Report | Nextpower (11/3) | +17.1% |
| Report | ADT Inc. (10/30) | +0.3% |
| Report | Genmab (10/29) | -3.8% |
| Filing | Axogen (10/29) | +4.3% |
The four earnings stories ranged from -6.4% to +4.0%. Among press-report cases Nextpower added 17.1% while Genmab lost 3.8%, so the same verdict led to different outcomes.
FAQ
Why did Rhythm Pharmaceuticals, Inc. stock go up?
+30.14%. Evidence: ~$252M. What to check next: Q2 beat reported; full-year outlook kept.
Why did Kyndryl Holdings, Inc. stock go up?
+28.04%. Evidence: ~$598M. What to check next: Reported $10B AstraZeneca offer.
Why did Duolingo, Inc. stock go up?
+25.99%. Evidence: ~$1.53B. What to check next: Earnings release, analyst target raises.